Abstract: Rasagiline mesylate (RM), an irreversible, selective inhibitor of MAO-B enzyme, is used in the treatment of Parkinson's disease as oral tablets. It has low oral bioavailability (36%) due to hepatic first pass metabolism. Oral route of administration is associated with nausea and vomiting. Hence present research work was aimed to develop intranasal RM-loaded mucoadhesive microemulsions for brain targeting via olfactory pathway. The microemulsions were developed using Box Behnken design and evaluated for globule size, PDI, Zeta potential, pH, viscosity and ex vivo permeation on excised porcine nasal mucosa. Based on drug solubility, Capmul MCM, Tween 20 and Transcutol P were selected as oil, surfactant and cosurfactant respectively. Microemulsions were prepared by water titration method. Pseudoternary phase diagrams were constructed and the levels of surfactants, oil were selected. The influence of independent variables such as oil, Smix and water on responses size, zeta potential and flux were studied with the help of polynomial equations, contour plots and 3D response surface plots generated by design expert software. Optimized microemulsion formulation (ME18) was composed of oil (Capmul MCM), Smix (Tween 20: Transcutol P; 1:1), water and drug in the ratio 5:42:65:5. The globule size, zeta potential and flux of the optimized microemulsion was 150 nm, -29.6 mV and 291.7 μg/cm 2 /h respectively. Mucoadhesive agent (Chitosan) was added at 0.5% concentration to optimized microemulsion formulation (MME18). The size, zeta potential and flux of the MME18 was 176.4 nm, 12.1 mV and 323.1 μg/cm 2 /h respectively. The flux of ME18 and MME 18 was significantly higher than drug solution. The enhancement ratio of MME 18 was 4.2 times to that of drug solution, indicating potential advantage of microemulsion formulation.
Introduction
Parkinson's disease (PD) is a common neurodegenerative disorder. Globally 6.2 million people affected by the disease and approximately 11 lakh people died due to parkinsonism in 2015 [1, 2] . PD symptoms include abnormal movements, such as tremor, rigidity, bradykinesia and postural instability. PD is characterized by progressive loss of dopaminergic neurons in substantia nigra of the mid brain region which result in imbalance between dopaminergic and cholinergic system. Dopamine functions as a neurotransmitter, coordinates movement and controls muscle tone [3, 4] .
Monoamine oxidase enzyme is responsible for oxidation of dopamine, generates hydroxyl free radical which results in damage of DNA, lipid membranes of neurons [5] . Rasagiline mesylate (RM) is a second-generation irreversible inhibitor of MAO-B enzyme with dopamine agonist activity [6] . Rasagiline mesylate was prescribed as monotherapy to treat early PD symptoms and in advanced cases as adjuvant along with levodopa [7] . Rasagiline is available in market as oral tablet (Azilect, 1mg) once daily. The oral route of administration is associated with GIT adverse effects such as headache, nausea, vomiting and dizziness. The bioavailability of orally administered drug is 36% as it undergoes hepatic first pass effect [8] . Therefore, there is a need to develop safe and effective formulation with improved bioavailability and reduced side effects. Nasal delivery of rasagiline could be a promising approach to improve the bioavailability [9] . Hence, mucoadhesive microemulsions of rasagiline mesylate for intranasal delivery were developed and optimized by Box Behnken experimental design.
Materials and Methods
Rasagiline mesylate was procured as a gift sample from Apotex Research Pvt. Ltd., (Bangalore, India). Capmul MCM was from Abitec Corporation Ltd. (Mumbai, India). Labrasol was from Gattefosse Pvt. Ltd. (Mumbai, India). Chitosan (low molecular weight), Transcutol P were from SigmaAldrich (Bangalore, India). Isopropyl myristate were purchased from Qualikems Fine Chem Pvt. Ltd (Vadodara, India). Propylene glycol, Polyethylene glycol 400, Tween 80 and Tween 20 were purchased from S.D Fine Chemicals (Mumbai, India).
Spectrophotometric determination, UV method
Rasagiline mesylate was dissolved in methanol and stock solution (1 mg/mL) was prepared. Different concentrations (20 to 200 µg/mL) of RM were prepared from stock solution by diluting with PBS pH 6.4. The absorbance of the samples was measured at 265 nm and calibration curve of rasagiline mesylate was plotted. The standard graph in methanol was also plotted [10] .
Solubility studies
The solubility of rasagiline mesylate in different oils, surfactants and cosurfactants was determined by equilibrium solubility method at room temperature, by adding excess amount of rasagiline mesylate into screw caped glass vial containing solvent. The mixture was agitated in water bath shaker at room temperature for 48 hours. The supernatant was filtered through 0.22 μm membrane filter and the filtrate was diluted suitably with methanol and the content of drug was determined by UV spectroscopy [11] .
Pseudoternary phase diagrams
Determination of microemulsion region and concentration range of ingredients was selected from pseudoternary phase diagrams. The surfactant and cosurfactant were studied at different ratios 1:1, 2:1, 3:1 and 1:2. To the oil and surfactant mixture at varying ratios of 1:9 to 9:1 water was added drop wise under stirring until homogeneous mixture turns to turbid. The amount of water added was noted and pseudoternary phase diagrams were constructed using Chemix software [12] .
Experimental design
A three level, three factor Box Behnken experimental design (Design expert software version 11, State Ease, Inc., MN) was used for formulation optimization [13] . Box Behnken design is categorized under response surface designs, with three levels, coded as -1, 0 and +1. The 3 major factors affecting the formulation, oil (A), Smix (B) and Water (C) were selected as independent variables and the dependent variables selected were globule size (Y1), zeta potential (Y2) and flux (Y3). Design matrix was comprised of 17 experimental runs. The polynomial equation generated for nonlinear quadratic model was as follows. Yi = b0 + b1A + b2B +b3C + b12AB + b13AC + b23BC + b11A 2 + b22B 2 + b33C 2 . Where Yi is the measured response of each factor level combination; b0 is intercept; b1, b2, b3, b12, b13, b23, b11, b22 and b33 are regression coefficients calculated from the measured experimental response Y. A, B and C are the coded levels of independent variables. The terms A 2 and AB represent the quadratic and interaction terms respectively.
Preparation method of microemulsion (ME) and mucoadhesive microemulsion (MME)
Microemulsions were prepared by water titration method. Accurately weighed amount of rasagiline mesylate was dissolved in oil (Capmul MCM) and Smix mixture by vortexing for 15 minutes. Water was added under stirring to make up the weight to form a clear and transparent microemulsion [14] . Chitosan dissolved in 1% acetic acid at 0.5% concentration was added to the optimized microemulsion and stirred continuously obtain clear formulation [15] .
Characterization of microemulsions
Globule size, zeta potential and Polydispersity index (PDI) The Globule size, PDI and Zeta potential were determined using Zeta sizer (Nano-ZS 90, Malvern Instruments Ltd.UK) on 100 times dilute the sample with water, at room temperature 90 o angle.
Measurement of viscosity, pH and drug content
The viscosity of the formulation was measured using Brookfield viscometer at room temperature, the pH of formulation was determined by using digital pH meter.
To determine the drug content formulations were suitably diluted in methanol and analyzed using UV spectrophotometer at 265 nm.
Ex vivo permeation studies
Ex vivo permeation studies were conducted using vertical diffusion cell apparatus mounted with excised porcine nasal mucosa. The porcine nose was collected from the local slaughter house and kept in Krebs bicarbonate ringers' solution and then nasal mucosa was carefully isolated using scalpel blade and blunt forceps. The isolated mucosa was rinsed with the PBS pH 6.4. The receptor compartment was filled with fresh buffer and the nasal mucosa was mounted between receptor and donor compartment allowed 30 min for equilibrate. The formulation was placed in donor compartment. Two ml of samples were withdrawn at specified time intervals up to 8 h and the samples were analyzed by UV method at 265 nm. The cumulative amount of rasagiline mesylate permeated at different time points was calculated using following formula
Where, Q= Cumulative amount of drug permeated Cn= Concentration of drug (μg/mL) in n th sample interval V= Volume of Franz diffusion cell, n-1 ΣCiS = Sum of drug concentration of sample (1 to n-1) i =1 multiplied with sample volume (S)
Analysis of permeation data A graph was plotted between cumulative amount of rasagiline mesylate permeated through the nasal mucosa (µg) and time (h) for each formulation. Flux of formulation (µg/cm 2 /h) at steady state (Jss) was calculated by dividing slope of linear portion of curve with effective mucosal area. Permeability coefficient (Kp) was calculated by dividing the steady state flux with the initial concentration of the rasagiline mesylate in the formulation. The ratio between steady state flux of formulation and drug solution was calculated to obtain enhancement ratio.
Check point analysis and optimization
To determine the significance of the main and interactive effects of factors on responses, analysis of variance (ANOVA) was performed. The independent variables were used at low, medium and high levels. The constraints chosen were minimum size, within the range of zeta potential and maximum flux.
Among the design matrix six formulations were selected by grid search for check point analysis. The formulations were prepared and evaluated for the response properties.
The experimental values were compared with predicted values and the percentage prediction error was calculated. The optimized formulation was selected based on desirability near to 1.
Stability studies
The physical stability of optimized formulations ME18 and MME18 were studied at refrigerated temperature and at room temperature for three months. The samples were analyzed for size, zeta potential and drug content after 3 months. Physical stability was evaluated by centrifugation of formulation at 10,000 rpm for 30 minutes [16] .
Results and Discussion
Calibration curve of rasagiline mesylate The calibration curve of rasagiline mesylate in PBS pH 6.4 and methanol showed good linearity with correlation coefficient value of 0.999. 
Solubility studies

Optimization of formulation by Box Behnken design
All the independent variables (factors) and the measured responses of 17 experimental runs were shown in Table 1 . The highmedium-low levels of oil were 5-10-15; Smix were 30-45-60, water were 25-45-65. The contour and 3D response surface plots were shown in Fig.3 and Fig. 4 . Note: Rasagiline mesylate equivalent 5 mg of rasagiline is common in all formulations, ME: Microemulsion; ZP: Zeta potential. Data shown as mean ± SD (n=3)
Fig.3. Contour plots showing effects of factors on responses
Fig.4. 3D response surface plots showing effects of factors on responses
Microemulsion characterization
The experimental measured values of mean globule size, Zeta potential and PDI of the formulations were shown in 
Data analysis
The experimental values were analyzed using ANOVA and the results were shown in Table 2 . The confirmation of model fit was by the difference between adjusted R 2 value and predicted R 2 value and P-Value (probability) greater than F-value [18] . The P-values for the responses size, zeta potential and flux were significantly high. Low PRESS value and high P-Value indicate the significance of the Quadratic model. The high F-value and nonsignificant lack of fit values of all the three responses indicate the model fitness. The difference between predicted R 2 value and Adjusted R 2 value was below 0.2 for all the three responses, indicating the validity of the model. Adequate Precision was used to measures the signal to noise ratio. It was greater than 4 for all the three responses, indicating a sufficient signal to noise move. The effect of independent factors on the dependent responses was quantified by polynomial equations, Contour plots and 3D response surface plots were shown in Fig.3 and Fig.4 
Effect of formulation variables on response Globule size (Y1)
The polynomial equation for the quadratic model in coded factors for the response size was given below Y1=+185.9+26.10A-9.70B+0.750C-3.0AB-2.85AC+8.40BC-12.08A 2 +4.12B 2 -2.22C 2 The A, BC, B 2 , B and A² are significant model terms influencing globule size in the decreasing order. The oil (A) has higher positive effect on globule size, Smix (B) has negative effect on size and water has less positive effect on size. Higher concentration of oil at constant level of Smix leads to higher size of globules due to increase in interfacial tension. Increase in the Smix leads to reduction in interfacial tension that result in decrease in globule size [19] .
Effect of formulation variables on response zeta potential (Y2)
The polynomial equation in coded factors of quadratic model for the zeta potential was given below Y2= +24.60-5.00A+1.7B+0.0375C-0.0500AB +0.2500AC-1.47BC+1.51A 2 -1.11B 2 +0.0375C 2 In this case A, B, BC and A² are significant model terms. Smix (B) showed positive effect as Smix content increased zeta potential also increased and oil (A) showed negative effect on zeta potential as oil increases zeta potential decreased [20] .
Effect of formulation variables on response Flux (Y3)
The polynomial equation in coded factors of quadratic model for the flux was given below Y3 =+220.04-75.39A-20.36B+8.25C+22.70AB-0.9750AC-1.52BC-14.87A 2 -6.37B 2 -1.09C 2 In this case A, B, AB and A² are significant model terms. Oil (A), Smix (B) had negative effect on formulation flux. As Oil and Smix increased within the studied range, formulation flux range was decreased. This is due to size of the formulation increased as a result nasal mucosa permeability was decreased and thermodynamic activity of the drug in the formulation was low which results in the reduction of flux respectively. Water has positive effect on flux, as water increased within the studied range flux also increased. This is due to hydration effect of water on the nasal mucosa leads to increase in the flux [21] .
Check point analysis
The Quadratic model was validated by check point analysis. The compositions measured and predicted responses of check point formulations were shown in Table 3 . The predicted values of size, zeta potential and flux were compared with the experimental values and the percentage prediction error was calculated. The percentage prediction error of all the check point formulations was below 5%, which indicates validity of the response surface model.
Formulation optimization
The desirability of the optimized formulation was 0.976. The composition of the optimized formulation (ME18) was oil (Capmul MCM), Smix (Tween 20: Transcutol P; 1:1) and water in the ratio of 5: 42: 65. The measured responses globule size, zeta potential, flux were 150.2 nm, -29.6 mV, 291.7 µg/cm 2 /h respectively. Flux and enhancement ratios of formulations were shown in Table 1 . The formulation with chitosan as mucoadhesive agent showed significant increase (323.1 µg/cm 2 /h) in the flux. Optimized formulations ME18 and MME18 showed significantly higher flux compared to drug solution (P <0.0001). Enhancement ratio of MME18 was 4.2 folds higher compared to drug solution [22] . 
Stability studies
The optimized formulations ME18 and MME 18 were physically stable for three months and the data was shown in Table 4 . There was no significant change observed in mean size, zeta potential and PDI values, after 3 months. 
